Illumina appoints Ragusa as CEO of Grail

By staff writers

October 15, 2021 -- Illumina has appointed Bob Ragusa as CEO of Grail, which currently operates as a separate and independent unit of Illumina after its August acquisition.

Ragusa succeeds Hans Bishop, who will continue to serve as advisor to the CEO through the end of 2021.

Ragusa has over 30 years of experience in genomics. He was previously Illumina's chief operating officer, where he was responsible for scaling the business to serve over 7,000 customers in more than 140 countries, the company said.

Ragusa holds a Master of Science in biomedical and electrical engineering from Carnegie Mellon University, as well as a Bachelor of Science in electrical engineering and a Master of Business Administration from the University of Connecticut.

Illumina, Merck partner on HRD test
Illumina and Merck have agreed to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency...
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Illumina donates $60M in NGS tools to build genomic network
Illumina is donating $60 million in next-generation sequencing (NGS) platforms, reagents, and support to create a comprehensive pathogen genomic...
Illumina partners with German university on genome sequencing
Illumina is joining forces with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen in Germany on whole-genome...
Illumina sees mixed results for Q4, fiscal year
Illumina increased its revenue for its fourth quarter, but revenues declined for the full year. The company's net income also increased for the most recent...

Copyright © 2021

Last Updated ls 10/15/2021 11:19:51 AM